The Application Notebook
Ingestion of DEG-adulterated glycerin excipients in pharmaceuticals and personal care products, such as toothpaste, mouth wash and medicinal syrups has caused systemic alcohol intoxication, acidosis and subsequent multiorgan failure that have led to hundreds of fatalities of children and adults.
Terri T. Christison, Brian M. De Borba and Jeffrey S. Rohrer, Dionex Corporation, Sunnyvale, California, USA.
Ingestion of DEG-adulterated glycerin excipients in pharmaceuticals and personal care products, such as toothpaste, mouth wash and medicinal syrups has caused systemic alcohol intoxication, acidosis and subsequent multiorgan failure that have led to hundreds of fatalities of children and adults.1 To help prevent future adulterations, the US FDA requested that the US Pharmacopeia (USP) revise the USP 32 NF 26 monograph to identify and quantify EG and DEG in sorbitol solutions at the maximum limit of 0.1%. The revised monograph (USP 33-NF 28) meets these criteria using GC-FID.2 To minimize the possibility of false positives, we used a confirmatory liquid chromatography method to determine 0.1% DEG in sorbitol solutions.3
Here, we describe the determination of 0.1% DEG in a sorbitol solution using a mixed-mode separation with an ion-exclusion (ICE) guard and a cation-exchange analytical column with pulsed amperometric detection (PAD) and a Pt working electrode. The method takes advantage of the selectivity of combining ion-exclusion, cation-exchange and reversed-phase properties to fully resolve DEG from other glycols and the large sorbitol matrix peak. Additionally, PAD provides a sensitive, selective and direct detection of DEG without cumbersome derivatization.
A Dionex ICS-3000 system was used in this study. DEG (25 µL) was separated using an IonPac ICE-AS1 guard column (4 × 50 mm) and IonPac CS14 analytical column (2 × 250 mm) with 100 mM methanesulphonic acid at 0.2 mL/min.3 DEG was detected using PAD with a disposable platinum electrode and three-potential waveform. Chromeleon 6.8 Chromatography Data System (CDS) software (Dionex) was used for system control and data processing. The 50 mg/mL sorbitol samples were spiked with 0.050 mg/mL DEG and diluted 1:4 for analysis.
Figure 1 shows the determination of 0.013 mg/mL DEG in 13 mg/mL sorbitol solution using a mixed-mode separation and PAD with 107% recovery. DEG is easily resolved from the large sorbitol peak and small unknown peaks (peaks 3 and 5). The method was sensitive with an LOD and LOQ of 3.1 and 10 µg/mL, respectively. This corresponds to 0.024 and 0.077% in a 13 mg/mL sorbitol solution. The calibration from 0.013 to 0.10 mg/mL DEG produced a correlation coefficient (r2 ) of 0.9993. The retention time and peak area precisions of 0.013 mg/mL DEG (n = 7) produced RSDs of 0.17 and 2.2, respectively.
Figure 1: Determination of diethylene glycol (DEG) in sorbitol by mixed-mode separation and PAD. Sample: 13 mg/mL sorbitol with 0.013 mg/mL DEG added. Peaks: 1 = void volume; 2 = sorbitol, 13.0 mg/mL; 3,5 = unknown; 4 = DEG, 0.014 mg/mL.
This method can be used as a primary method for determining DEG in sorbitol solutions or to confirm the results obtained by GC-FID. The method directly, accurately and selectively determines DEG in mg/mL sorbitol solutions at concentrations below the USP monograph limit of 0.1% DEG. Samples suspected of adulteration need only be diluted and analysed to evaluate their safety.
1. K.L. O'Brien et al., JAMA, 279(15), 1175–1180 (1998).
2. United States Pharmacopeial. Sorbitol Solution, Pharmacopeial Revision Bulletin. To be printed in USP 33, NF 28 First Supplement, released 1 February 2010, official 1 August 2010.
3. Dionex Corporation. Determination of ethylene glycol and diethylene glycol in a sorbitol solution, Application Note 246, LPN 2505, Sunnyvale, California, USA, 2010.
IonPac and Chromeleon are registered trademarks of Dionex Corporation.
Dionex Corporation
1228 Titan Way, PO Box 3603, Sunnyvale, California 94088, USA
tel. +1 408 737 0700 fax +1 408 730 9403
Website: www.dionex.com
SEC-MALS of Antibody Therapeutics—A Robust Method for In-Depth Sample Characterization
June 1st 2022Monoclonal antibodies (mAbs) are effective therapeutics for cancers, auto-immune diseases, viral infections, and other diseases. Recent developments in antibody therapeutics aim to add more specific binding regions (bi- and multi-specificity) to increase their effectiveness and/or to downsize the molecule to the specific binding regions (for example, scFv or Fab fragment) to achieve better penetration of the tissue. As the molecule gets more complex, the possible high and low molecular weight (H/LMW) impurities become more complex, too. In order to accurately analyze the various species, more advanced detection than ultraviolet (UV) is required to characterize a mAb sample.